Sign in
Safety and Efficacy of Brepocitinib, a TYK2/JAK1 Inhibitor, in Active Non-Infectious Uveitis: 24-Week Results from a 52-Week Phase 2 Study (NEPTUNE)
Robert C. Wang, MD, FASRS
Annual Meeting Talks
2024
Post Hoc Analysis of Suprachoroidal Injection Experience Across Retinal Disease Indications
Christopher R Henry, MD
2020
Outcomes of Children With Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy
Arjun B Sood, MD
2023
Category: Inflammatory and Infectious Diseases- Helminthic Infections